Panelists discuss how immunoglobulin A (IgA) nephropathy’s progressive nature and significant economic impact demand a shift in payer perspective toward investing in disease-modifying therapies that, ...

Panelists discuss how economic considerations in immunoglobulin A (IgA) nephropathy medication management vary dramatically across chronic kidney disease (CKD) stages, with early intervention costs ...

Panelists discuss how promising ongoing and upcoming clinical trials may reshape sequencing strategies in ALK+ non–small cell lung cancer (NSCLC).

Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, ...

The Congressional Budget Office estimates the package would add $2.4 trillion to the national deficit over a decade and leave ...

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative ...

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Tariff increases threaten the US economy and health care costs, impacting managed care affordability and member financial ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.